Statin Safety Evidence, Clarified: An Umbrella Review for Scientific Communication
Challenge The safety of statins has been extensively studied, resulting in a large and heterogeneous body of systematic reviews and meta-analyses. Translating this complex evidence base into clear, credible insights for medical affairs communication requires a structured and methodologically robust synthesis. Solution Clevidence designed and conducted an umbrella review, consolidating evidence from systematic reviews and […]
Bridging the Evidence Gap in HTA: Indirect Comparisons to Support Reimbursement Decision-Making
Challenge A pharmaceutical company sought to demonstrate the efficacy and safety of a novel therapy for adults with persistent urinary symptoms who had previously received first-line pharmacological treatment. A key challenge in the HTA evaluation was the absence of head-to-head clinical trials comparing the therapy with the primary comparator considered relevant by the HTA authority. […]
Evaluating the Impact of the COVID-19 Pandemic on NHS Cancer Screening and Outcomes
Client: A Healthcare Organization Challenge:A healthcare organization sought to assess the COVID-19 pandemic’s impact on NHS cancer screening performance. They aimed to determine how disruptions affected cancer morbidity and mortality rates, posing significant challenges for public health management. Solution Provided by Clevidence:Clevidence was engaged to conduct a comprehensive study involving several key steps: Results:The study […]
Enhancing Awareness of the Relationship Between Two Clinical Conditions
Client: A Pharmaceutical Company Challenge:A pharmaceutical company sought to create communication materials for medical sales visits and scientific exchange meetings to raise awareness of the relationship between two clinical conditions. The objective was to highlight data on epidemiology, risk factors, and the importance of monitoring patients with one condition for potential development of the other. […]
Cost-Effectiveness Assessment for an Orphan Drug in a Rare Autoimmune Disease
Client: A Leading Pharmaceutical Company Challenge:A pharmaceutical company sought to adapt a cost-effectiveness model for an orphan drug targeting a rare autoimmune disease. The goal was to determine the incremental cost-effectiveness ratio (ICER), estimate the budget impact, and assist the company in negotiating pricing and a capped contract for utilization within NHS hospitals. Solution Provided […]
Comparative Effectiveness of Treatment Options for Advanced Stage Cancer with Genetic Alterations to Support HTA
Client: A Leading Pharmaceutical Company Challenge:The client aimed to assess the efficacy and safety of a novel treatment (Drug A) in adult patients with advanced stage cancer harboring specific genetic alterations. The objective was to evaluate its effectiveness alongside standard chemotherapy and immunotherapy options in patients who had previously undergone systemic therapy. Solution Provided by […]